LLY

1,005.56

-1.5%↓

JNJ

229.79

+0.06%↑

ABBV

210.81

+1.69%↑

UNH

399.45

-0.62%↓

AZN

185.27

-0.71%↓

LLY

1,005.56

-1.5%↓

JNJ

229.79

+0.06%↑

ABBV

210.81

+1.69%↑

UNH

399.45

-0.62%↓

AZN

185.27

-0.71%↓

LLY

1,005.56

-1.5%↓

JNJ

229.79

+0.06%↑

ABBV

210.81

+1.69%↑

UNH

399.45

-0.62%↓

AZN

185.27

-0.71%↓

LLY

1,005.56

-1.5%↓

JNJ

229.79

+0.06%↑

ABBV

210.81

+1.69%↑

UNH

399.45

-0.62%↓

AZN

185.27

-0.71%↓

LLY

1,005.56

-1.5%↓

JNJ

229.79

+0.06%↑

ABBV

210.81

+1.69%↑

UNH

399.45

-0.62%↓

AZN

185.27

-0.71%↓

Inicio・Lista de Acciones・Merck & Co Inc.

Merck & Co Inc.

Abierto

SectorSanidad

112.68 -0.76

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

112.61

Máximo

114.04

Métricas clave
By Trading Economics
Ingresos	-7.2B -4.2B
Ventas	-114M 16B
P/B Media del Sector	31.347 51.415
BPA	-1.28
Rentabilidad por dividendo	2.94
Margen de beneficios	-26.053
Empleados	73,000
EBITDA	-6.2B -1.9B

Recomendaciones
By TipRanks
Recomendaciones	Comprar
Estimación a 12 Meses	+19.53% upside

Dividendos
By Dow Jones
Rentabilidad por dividendo Media del Sector	2.94% 2.34%
Próximas Ganancias	4 ago 2026
Fecha Próximo Dividendo	7 jul 2026
Próxima Fecha de Ex Dividendo	15 jun 2026

Estadísticas de Mercado
By TradingEconomics
Capitalización Mercado	2.6B 275B
Apertura anterior	113.44
Cierre anterior	112.68

Noticias sobre sentimiento de mercado

By Acuity

43%

57%

138 / 346 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Bearish Evidence

76.03 / 83.28 Soporte y Resistencia

Merck & Co Inc. Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

30 abr 2026, 14:20 UTC

Ganancias

Merck 1Q Sales Rise on Continued Keytruda Growth -- Update

30 abr 2026, 10:45 UTC

Ganancias

Merck 1Q Sales Rise on Continued Keytruda Growth

5 may 2026, 18:12 UTC

Ganancias

BioNTech to Slash 22% of Workforce as Losses Widen. The Stock Falls. -- Barrons.com

5 may 2026, 13:54 UTC

Ganancias

BioNTech to Slash 25% of Workforce as Losses Widen. The Stock Falls. -- Barrons.com

5 may 2026, 12:48 UTC

Adquisiciones, fusiones, absorciones

Merck Cites Costs Associated With Advancing TERN-701 and Financing >MRK

5 may 2026, 12:48 UTC

Adquisiciones, fusiones, absorciones

Merck: GAAP and Adj EPS Expected to Be Negatively Impacted by About 12c/Shr in 2026 >MRK

5 may 2026, 12:47 UTC

Adquisiciones, fusiones, absorciones

Merck: Transaction Expected to Be Accounted for as Asset Acquisition, Resulting in Chg of About $5.8 B, or $2.35/Shr, Included in 2Q and FY26 Results >MRK

5 may 2026, 12:45 UTC

Adquisiciones, fusiones, absorciones

Merck Completes Acquisition Of Terns Pharmaceuticals, Inc. >MRK TERN

1 may 2026, 18:35 UTC

Ganancias

Moderna's Covid Vaccine Is Driving Growth Again. The Stock Is Down Anyway. -- Barrons.com

1 may 2026, 14:53 UTC

Ganancias

Moderna's Covid Vaccine Is Driving Growth Again. The Stock Is Down Anyway. -- Barrons.com

30 abr 2026, 13:27 UTC

Ganancias

Merck Stock Falls After Earnings. It's Working on Ways to Blunt Future Lost Keytruda Sales. -- Barrons.com

30 abr 2026, 10:47 UTC

Ganancias

Update: Merck Stock Rises on Earnings. These Problems Loom Larger Than Keytruda Patent Cliff. -- Barrons.com

30 abr 2026, 10:30 UTC

Ganancias

Merck: Also Anticipate EPS Will Be Negatively Affected by About 12c Over Remainder of 2026 Following Close of Terns Deal >MRK

30 abr 2026, 10:30 UTC

Ganancias

Merck Raises 2026 View To Adj EPS $5.04-Adj EPS $5.16 Vs Prior View $5-$5.15 >MRK

30 abr 2026, 10:30 UTC

Ganancias

Merck: 2026 Outlook Doesn't Reflect Any Impact From Proposed Acquisition of Terns Pharmaceuticals, Which Is Expected to Close in May and Result in One-Time Charge of About $2.35/Shr >MRK

30 abr 2026, 10:30 UTC

Ganancias

Merck: Sales Outlook Includes Positive Impact From Forex of About 1% at Mid-April 2026 Exchange Rates >MRK

30 abr 2026, 10:30 UTC

Ganancias

Merck: Adj EPS Outlook Also Reflects One-Time Charge of $3.62/Shr for Acquisition of Cidara >MRK

30 abr 2026, 10:30 UTC

Ganancias

Merck: Adj EPS Outlook Includes Positive Impact From Forex of About 10c/Shr at Mid-April 2026 Exchange Rates >MRK

30 abr 2026, 10:30 UTC

Ganancias

Merck Narrows 2026 View To Sales $65.8B-$67B Vs Prior View $65.5B-$67B >MRK

30 abr 2026, 10:30 UTC

Ganancias

Merck: Latest 1Q Includes Charge of $3.62/Share for the Acquisition of Cidara >MRK

30 abr 2026, 10:30 UTC

Ganancias

Merck: 1Q Gardasil/Gardasil 9 Sales Also Reflect Lower Sales in U.S. Primarily Due to Unfavorable Public-Sector Purchasing Patterns, Partially Offset by Higher Net Pricing >MRK

30 abr 2026, 10:30 UTC

Ganancias

Merck 1Q Gardasil/Gardasil 9 Sales Down 19% >MRK

30 abr 2026, 10:30 UTC

Ganancias

Merck: Lower 1Q Januvia/Janumet Sales Due to Lower Demand and Net Pricing in U.S., Lower Demand in China and Most Other International Markets Due to Generic Competition >MRK

30 abr 2026, 10:30 UTC

Ganancias

Merck: Pleased With Progress and Excited for What's Ahead, as We Enter Particularly Robust Period of Phase 3 Data Readouts and Deliver on Promise of Our Pipeline for Patients >MRK

30 abr 2026, 10:30 UTC

Ganancias

Merck 1Q Winrevair Sales $525M, Up 88%, Reflecting Continued Uptake in U.S. and Early Launch Uptake in Certain Intl Mkts, Especially Japan and Europe >MRK

30 abr 2026, 10:30 UTC

Ganancias

Merck: 1Q Animal Health Sales Growth Attributable to Performance in Both Livestock and Companion Animal Product Portfolios >MRK

30 abr 2026, 10:30 UTC

Ganancias

Merck: Lower 1Q Gardasil/Gardasil 9 Sales Primarily Due to Lower Demand in China as Well as Lower Sales in Japan Following National Catch-Up Immunization Program >MRK

30 abr 2026, 10:30 UTC

Ganancias

Merck 1Q Pharmaceutical Sales Up 5% >MRK

30 abr 2026, 10:30 UTC

Ganancias

Merck 1Q Animal Health Sales Up 13% >MRK

30 abr 2026, 10:30 UTC

Ganancias

Merck 1Q Sales $16.29B >MRK

Comparación entre iguales

Cambio de precio

Merck & Co Inc. previsión

Precio Objetivo

By TipRanks

19.53% repunte

Estimación a 12 Meses

Media 135.61 USD 19.53%

Máximo 179 USD

Mínimo 112 USD

De acuerdo con 20 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Merck & Co Inc. Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

20 ratings

Comprar

Mantener

Vender

De acuerdo con 20 analistas que ofrecen calificaciones bursátiles a para Merck & Co Inc. Dist en los últimos 3 meses.

Puntuación técnica

By Trading Central

76.03 / 83.28Soporte y Resistencia

Recent bearish events outweigh bullish events.

All events are bearish.

Sentimiento

By Acuity

138 / 346 Clasificación en Sanidad

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de Merck & Co Inc.

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes under the Keytruda, Bridion, Adempas, Lagevrio, Belsomra, Simponi, and Januvia brands, as well as vaccine products consisting of preventive pediatric, adolescent, and adult vaccines under the Gardasil/Gardasil 9, ProQuad, M-M-R II, Varivax, RotaTeq, Live Oral, Vaxneuvance, Pneumovax 23, and Vaqta names. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. vIt has development and commercialization agreement for three of Daiichi Sankyo's deruxtecan ADC candidates, which include patritumab deruxtecan, ifinatamab deruxtecan, and raludotatug deruxtecan for the treatment of multiple solid tumors both as monotherapy and/or in combination with other treatments; and AstraZeneca PLC to co-development and co-commercialize AstraZeneca's Lynparza products for multiple cancer types, and Koselugo for multiple indications. It also has licensed to develop, manufacture and commercialize LM-299, a novel investigational PD-1/VEGF bispecific antibody from LaNova. The company also has a collaboration agreement with Eisai Co., Ltd., Bayer AG, and Ridgeback Biotherapeutics LP, as well Moderna, Inc. Merck & Co., Inc. was founded in 1891 and is headquartered in Rahway, New Jersey.